Sciverse Solutions develops diagnostic platforms utilizing microfluidics, biosensors, and artificial intelligence to enable ultra-sensitive biomarker detection and instant complete blood count (CBC) testing at the point of care. Their technology addresses the need for accessible and rapid diagnostic solutions, improving patient outcomes and healthcare delivery efficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional complete blood count (CBC) testing requires centralized lab equipment, limiting accessibility and turnaround time, especially in point-of-care settings. Existing biomarker detection methods often lack the sensitivity needed for early disease diagnosis and monitoring.
Solution
Sciverse Solutions develops point-of-care diagnostic platforms that combine microfluidics, biosensors, and artificial intelligence to enable rapid and ultra-sensitive biomarker detection and complete blood count (CBC) testing. Their SciLisa platform offers enhanced sensitivity for early disease detection, while MyCount Xpress provides instant CBC results from finger-prick samples at the doctor's desk. These modular technologies aim to improve patient outcomes and healthcare delivery efficiency by providing accessible and timely diagnostic information.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and research institutions seeking rapid, accessible, and highly sensitive point-of-care diagnostic solutions.
Features
- SciLisa: Ultra-sensitive biomarker detection platform for early disease diagnosis
- MyCount Xpress: Point-of-care CBC testing from finger-prick samples
- AI-powered data analysis for accurate and efficient results interpretation
- Microfluidics technology for precise sample handling and analysis
- Modular design for flexible integration into various point-of-care settings